Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $28.86

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on […]

Related Keywords

Canada ,Switzerland ,Swiss ,Houte Hans Van ,Jpmorgan Chase Co ,Royal Bank ,Dimensional Fund Advisors ,Nurix Therapeutics Inc ,Nurix Therapeutics Company Profile ,Securities Exchange Commission ,Metlife Investment Management ,Swiss National Bank ,Nasdaq ,Needham Company ,Nurix Therapeutics ,Get Free Report ,Marketbeat Ratings ,Hans Van ,Exchange Commission ,National Bank ,Life Investment Management ,Fund Advisors ,Get Free ,Casitasb Lineage ,Nurix Therapeutics Daily ,Nasdaq Nrix ,Winrix ,Medical ,Ratings ,Consensus ,